ClinicalTrials.Veeva

Find clinical trials for Ovarian Cancer in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Ovarian Epithelial Carcinoma
Cancer
Carcinoma
Endometrial Cancer
Fallopian Tube Cancer
Breast Cancer
Triple Negative Breast Cancer

Ovarian Cancer trials near Paris, Île-de-France, FRA:

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients (DUO-O)

followed by maintenance durvalumab and bevacizumab or durvalumab, bevacizumab and olaparib in patients with newly diagnosed advanced ovarian ...

Active, not recruiting
Advanced Ovarian Cancer
Drug: Durvalumab placebo
Drug: Bevacizumab

Phase 3

AstraZeneca
AstraZeneca

Paris, France and 213 other locations

of olaparib maintenance monotherapy in relapsed high grade serous ovarian cancer (HGSOC) patients (including patients with primary ...

Active, not recruiting
Relapsed Ovarian Cancer
Following Complete or Partial Response to Platinum Based Chemotherapy
Drug: Olaparib 300mg tablets
Drug: Placebo to match olaparib 300mg

Phase 3

AstraZeneca
AstraZeneca

Paris Cedex 5, France and 125 other locations

the safety and efficacy of avutometinib (VS-6766) monotherapy and in combination with defactinib in subjects with recurrent Low-Grade Serous Ovarian...

Active, not recruiting
Low Grade Ovarian Serous Adenocarcinoma
Ovarian Cancer
Drug: avutometinib (VS-6766) and defactinib
Drug: avutometinib (VS-6766)

Phase 2

Verastem

Paris, France and 46 other locations

clinical activity, pharmacokinetics (PK), and pharmacodynamics (PD) of ZN-c3 in combination with niraparib in subjects with platinum-resistant ovarian...

Enrolling
Fallopian Tube Cancer
Ovarian Cancer
Drug: Niraparib
Drug: ZN-c3

Phase 1, Phase 2

K-Group Beta

Villejuif, France and 18 other locations

of alpelisib and olaparib compared with single agent cytotoxic chemotherapy in patients with platinum resistant or refractory high-grade serous ovarian...

Active, not recruiting
Ovarian Cancer
Drug: Pegylated liposomal doxorubicin (PLD)
Drug: Olaparib

Phase 3

Novartis
Novartis

Paris, France and 93 other locations

Olaparib Monotherapy in Patients with BRCA Mutated Ovarian Cancer following First Line Platinum Based Chemotherapy....

Active, not recruiting
Advanced Ovarian Cancer
FIGO Stage III-IV
Drug: Olaparib 300mg tablets

Phase 3

AstraZeneca
AstraZeneca

Paris, France and 176 other locations

chemotherapy and in maintenance, in patients presenting epithelial ovarian cancer (including patients with primary peritoneal and /...

Active, not recruiting
Ovarian Cancer
Drug: placebo + avastin + platinum-based chemotherapy
Drug: atezolizumab + avastin + platinum-based chemotherapy

Phase 3

ARCAGY/ GINECO GROUP

Paris, France and 74 other locations

to explore the safety and feasibility in neo-adjuvant first-line ovarian cancer (including patients with primary peritoneal or fall...

Active, not recruiting
Ovarian Cancer
Drug: ARM B Durvalumab/Tremelimumab/chemotherapy association
Drug: ARM A Durvalumab/chemotherapy association

Phase 1, Phase 2

ARCAGY/ GINECO GROUP

Paris, France and 10 other locations

The purpose of this study is to assess the efficacy and safety of abemaciclib and letrozole for treatment of estrogen receptor-positive rare ovarian...

Enrolling
Low Grade Serous Ovarian Carcinoma
Adult Type Granulosa Cell Tumor
Drug: Abemaciclib
Drug: Letrozole

Phase 2

Universitaire Ziekenhuizen KU Leuven

Paris, Île-de-France, France and 11 other locations

in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian...

Enrolling
Primary Peritoneal Cancer
Fallopian Tube Cancer
Biological: Pembrolizumab
Biological: Nemvaleukin

Phase 3

Mural Oncology

Paris, France and 131 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems